Abstract
Monoclonal antibodies capable of recognizing antigens with high affinity and specificity represent a wellestablished class of biological agents. Since the development of hybridoma technology in 1975, advances in recombinant DNA technologies and computational and biophysical methods have allowed us to develop a better understanding of the relationships between antibody sequence, structure, and function. These advances enable us to manipulate antibody sequences with the goal of improving upon, or creating new biological or biophysical properties. In this review we will focus on recent successes in using structure-guided computational methods to design antibodies and antibody-like molecules with optimized affinity and specificity to antigen and for enhancing protein stability.
Keywords: Antibody engineering, structure-based design, affinity maturation, effector function, protein stability
Current Computer-Aided Drug Design
Title: Structure-Guided Design of Antibodies
Volume: 6 Issue: 2
Author(s): Justin A. Caravella, Deping Wang, Scott M. Glaser and Alexey Lugovskoy
Affiliation:
Keywords: Antibody engineering, structure-based design, affinity maturation, effector function, protein stability
Abstract: Monoclonal antibodies capable of recognizing antigens with high affinity and specificity represent a wellestablished class of biological agents. Since the development of hybridoma technology in 1975, advances in recombinant DNA technologies and computational and biophysical methods have allowed us to develop a better understanding of the relationships between antibody sequence, structure, and function. These advances enable us to manipulate antibody sequences with the goal of improving upon, or creating new biological or biophysical properties. In this review we will focus on recent successes in using structure-guided computational methods to design antibodies and antibody-like molecules with optimized affinity and specificity to antigen and for enhancing protein stability.
Export Options
About this article
Cite this article as:
A. Caravella Justin, Wang Deping, M. Glaser Scott and Lugovskoy Alexey, Structure-Guided Design of Antibodies, Current Computer-Aided Drug Design 2010; 6 (2) . https://dx.doi.org/10.2174/157340910791202469
DOI https://dx.doi.org/10.2174/157340910791202469 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes
Current Cardiology Reviews Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Advances in the Knowledge and Clinical Applications of Lactic Acid Bacteria as Probiotics in the Urogenital Tract
Current Women`s Health Reviews Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Pharmacological Targeting of the Hsp70 Chaperone
Current Topics in Medicinal Chemistry Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) New Alkyl-Lipid Blockers of SK3 Channels Reduce Cancer Cell Migration and Occurrence of Metastasis
Current Cancer Drug Targets The Role of STATs in Apoptosis
Current Molecular Medicine QSAR Study of Androstenedione Analogs as Aromatase Inhibitors
Letters in Drug Design & Discovery Computer-Aided Drug Design Methodologies Toward the Design of Anti-Hepatitis C Agents
Current Topics in Medicinal Chemistry Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies The Use of Cyclodextrins Nanoparticles for Oral Delivery
Current Medicinal Chemistry HIV Infection Induces Morphometrical Changes on the Oral (Buccal Mucosa and Tongue) Epithelial Cells
Current HIV Research EH-42: A Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells through Suppressing STAT3 Signaling Pathway
Current Cancer Drug Targets Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
Current Molecular Medicine